METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA

(19)

(11)

EP 2 139 484 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.08.2013 Bulletin 2013/34

(45)	Mention of the grant of the patent:
	17.07.2013 Bulletin 2013/29

(21)	Application number: 08742677.1

(22)	Date of filing: 09.04.2008

(51)

International Patent Classification (IPC):

A61K 31/517^(2006.01)
A61K 45/06^(2006.01)
A61K 31/337^(2006.01)
A61P 35/00^(2006.01)

A61K 31/519^(2006.01)
A61K 31/282^(2006.01)
A61K 31/4745^(2006.01)

(86)	International application number:
	PCT/US2008/004573

(87)	International publication number:
	WO 2008/124161 (16.10.2008 Gazette 2008/42)

(54)	METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA VERFAHREN ZUR KREBSBEHANDLUNG MIT PI3K-ALPHA-PYRIDOPYRIMIDONHEMMERN MÉTHODES DE TRAITEMENT DU CANCER À L'AIDE D'INHIBITEURS DE PI3K ALPHA À BASE DE PYRIDOPYRIMIDINONE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA MK RS

(30)

Priority:

10.04.2007 US 922899 P

(43)	Date of publication of application:
	06.01.2010 Bulletin 2010/01

(60)	Divisional application:
	12172484.3

(73)	Proprietor: Exelixis, Inc.
	South San Francisco, CA 94080 (US)

(72)	Inventors:
	LAMB, Peter Oakland, California 94610 (US) MATTHEWS, David San Francisco, California 94127 (US)

(74)	Representative: Main, Malcolm Charles
	Murgitroyd & Company Immeuble Atlantis 55 Allee Pierre Ziller 06560 Valbonne - Sophia Antipolis 06560 Valbonne - Sophia Antipolis (FR)

(56)

References cited: :

WO-A-2004/006846
WO-A-2007/044698
US-A1- 2004 009 993

WO-A-2005/105801
WO-A-2008/021389

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).